Full Paper
crob. Agents 2012, 40, 95; f) L. P. Jordheim, D. Durantel, F.
Zoulim, C. Dumontet, Nat. Rev. Drug Discovery 2013, 12,
447.
Vuilleumier, F. de Nanteuil, J. Waser, Org. Lett. 2015, 17,
1030.
[7] a) P. Ciapetti, M. Taddei, Tetrahedron 1998, 54, 11305;
b) H.-J. Gi, Y. Xiang, R. F. Schinazi, K. Zhao, J. Org. Chem.
1997, 62, 88.
[2] a) U. Niedball, H. Vorbrꢂggen, Angew. Chem. Int. Ed. Engl.
1970, 9, 461; b) G. Shaw, R. N. Warrener, M. H. Maguire,
R. K. Ralph, J. Chem. Soc. 1958, 2294; Reviews: c) M. T.
Crimmins, Tetrahedron 1998, 54, 9229; d) H. Vorbrꢂggen, C.
Ruh-Polenz, Handbook of Nucleoside Synthesis, John Wiley
& Sons, New York, 2001; e) Antiviral Nucleosides: Chiral
Synthesis and Chemotherapy (Ed.: C. K. Chu), Elsevier,
Amsterdam, 2003; f) C. Mathe, C. Perigaud, Eur. J. Org.
Chem. 2008, 1489; g) G. Romeo, U. Chiacchio, A. Corsaro,
P. Merino, Chem. Rev. 2010, 110, 3337; h) Chemical Synthe-
sis of Nucleoside Analogues (Ed.: P. Merino), John Wiley &
Sons, Hoboken NJ, 2013; i) O. Boutureira, M. I. Matheu, Y.
Diaz, S. Castillon, Chem. Soc. Rev. 2013, 42, 5056; j) L.
Scagnelli, M. G. Memeo, S. Carosso, B. Bovio, P. Quadrelli,
Eur. J. Org. Chem. 2013, 3835.
[3] a) S. Daluge, R. Vince, Tetrahedron Lett. 1976, 17, 3005;
b) R. Singh, R. Vince, Chem. Rev. 2012, 112, 4642; c) J.
Velcicky, A. Lanver, J. Lex, A. Prokop, T. Wieder, H. G.
Schmalz, Chem. Eur. J. 2004, 10, 5087; d) W. J. Choi, J. G.
Park, S. J. Yoo, H. O. Kim, H. R. Moon, M. W. Chun, Y. H.
Jung, L. S. Jeong, J. Org. Chem 2001, 66, 6490; e) B. M.
Trost, G. H. Kuo, T. Benneche, J. Am. Chem. Soc. 1988, 110,
621; f) B. M. Trost, L. S. Kallander, J. Org. Chem. 1999, 64,
5427; g) L. F. Tietze, C. Stadler, N. Bçhnke, G. Brasche, A.
Grube, Synlett 2007, 485; h) M. J. Mulvihill, J. L. Gage, M. J.
Miller, J. Org. Chem 1998, 63, 3357; i) G. A. Boyle, C. D.
Edlin, Y. F. Li, D. C. Liotta, G. L. Morgans, C. C. Musonda,
Org. Biomol. Chem. 2012, 10, 1870.
[8] P. Arsenyan, A. Petrenko, E. Paegle, S. Belyakov, Mende-
leev Commun. 2011, 21, 326.
[9] K. S. Toti, M. Derudas, C. McGuigan, J. Balzarini, S. Van
Calenbergh, Eur. J. Med. Chem. 2011, 46, 3704.
[10] B. Nawrot, O. Michalak, S. Olejniczak, M. W. Wieczorek, T.
Lis, W. Stec, Tetrahedron 2001, 57, 3979.
[11] a) C. G. Espino, K. W. Fiori, M. Kim, J. Du Bois, J. Am.
Chem. Soc. 2004, 126, 15378; b) F. Gonzalez-Bobes,
M. D. B. Fenster, S. Kiau, L. Kolla, S. Kolotuchin, M. Sou-
meillant, Adv. Synth. Catal. 2008, 350, 813.
[12] Yield calculated from diazomalonate. If calculated with
uracil as the limiting reagent: 13b: 33%, 14: 38%.
[13] a) T. Kametani, K. Kigasawa, M. Hiiragi, K. Wakisaka, K.
Nakazato, K. Ichikawa, K. Fukawa, O. Irino, N. Nishimura,
T. Okada, J. Med. Chem. 1982, 25, 1219; b) J. Yamashita, M.
Yasumoto, S. Takeda, H. Matsumoto, N. Unemi, J. Med.
Chem. 1989, 32, 136; c) G. Y. Song, V. Paul, H. Choo, J.
Morrey, R. W. Sidwell, R. F. Schinazi, C. K. Chu, J. Med.
Chem. 2001, 44, 3985.
[14] NMR data of compound 28 corresponded to the proposed
structure; however, this compound could not be purified for
complete characterization.
[15] a) A. P. Krapcho, G. A. Glynn, B. J. Grenon, Tetrahedron
Lett. 1967, 8, 215; b) A. P. Krapcho, E. G. E. Jahngen, A. J.
Lovey, F. W. Short, Tetrahedron Lett. 1974, 15, 1091; c) N.
Pꢀrez-Hernꢄndez, M. Febles, C. Pꢀrez, R. Pꢀrez, M. L. Ro-
drꢅguez, C. Foces-Foces, J. D. Martꢅn, J. Org. Chem. 2006,
71, 1139; d) K. C. Nicolaou, A. A. Estrada, M. Zak, S. H.
Lee, B. S. Safina, Angew. Chem. Int. Ed. 2005, 44, 1378;
e) S. Das, K. Mçller, K. Junge, M. Beller, Chem. Eur. J.
2011, 17, 7414.
[16] a) K. C. Nicolaou, V. A. Adsool, C. R. H. Hale, Org. Lett.
2010, 12, 1552; b) P. Dupau, R. Epple, A. Thomas, V. Fokin,
K. Barr. Sharpless, Adv. Synth. Catal. 2002, 344, 421.
[17] Attempts to directly reduce the crude product in one-pot
were not successful.
[4] a) H.-U. Reissig, R. Zimmer, Chem. Rev. 2003, 103, 1151;
b) M. Yu, B. L. Pagenkopf, Tetrahedron 2005, 61, 321;
c) C. A. Carson, M. A. Kerr, Chem. Soc. Rev. 2009, 38,
3051; d) F. De Simone, J. Waser, Synthesis 2009, 3353;
e) T. F. Schneider, J. Kaschel, D. B. Werz, Angew. Chem. Int.
Ed. 2014, 53, 5504.
[5] (3+2) Annulation with imido-cyclopropanes: a) F. de Nan-
teuil, J. Waser, Angew. Chem. Int. Ed. 2011, 50, 12075; b) F.
Benfatti, F. de Nanteuil, J. Waser, Chem. Eur. J. 2012, 18,
4844; c) F. Benfatti, F. de Nanteuil, J. Waser, Org. Lett.
2012, 14, 386; d) F. de Nanteuil, E. Serrano, D. Perrotta, J.
Waser, J. Am. Chem. Soc. 2014, 136, 6239; e) E. Serrano, F.
de Nanteuil, J. Waser, Synlett 2014, 25, 2285; Other reac-
tions with imido-cyclopropanes: f) F. de Nanteuil, J. Loup, J.
Waser, Org. Lett. 2013, 15, 3738; g) R. Tejero, A. Ponce, J.
Adrio, J. C. Carretero, Chem. Commun. 2013, 49, 10406;
h) A. R. Rivero, I. Fernandez, M. A. Sierra, Org. Lett. 2013,
15, 4928; (4+2) Annulations with imido-cyclobutanes: i) F.
de Nanteuil, J. Waser, Angew. Chem. Int. Ed. 2013, 52, 9009;
For a review, see: j) F. de Nanteuil, F. De Simone, R. Frei, F.
Benfatti, E. Serrano, J. Waser, Chem. Commun. 2014, 50,
10912.
[18] L. Beigelman, P. Haeberli, D. Sweedler, A. Karpeisky, Tetra-
hedron 2000, 56, 1047.
[19] G. R. Geen, P. M. Kincey, B. M. Choudary, Tetrahedron
Lett. 1992, 33, 4609.
[20] W. Lehnert, Tetrahedron 1973, 29, 635.
[21] A. R. A. S. Deshmuck, D. G. Panse, B. M. Bhawal, Synth.
Commun. 1999, 10, 1801.
[22] A. R. Maguire, W.-D. Meng, S. M. Roberts, A. J. Willetts, J.
Chem. Soc. Perkin Trans. 1 1993, 1795.
[23] Bristol-Myers Squibb Company, Patent: WO2003/99286 A1,
2003; Location in patent: p. 89.
Received: November 10, 2015
Accepted: December 14, 2015
Published online: && &&, 0000
[6] a) S. Racine, F. de Nanteuil, E. Serrano, J. Waser, Angew.
Chem. Int. Ed. 2014, 53, 8484; b) D. Perrotta, S. Racine, J.
Isr. J. Chem. 0000, 00, 1 – 13
ꢁ 0000 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
&
12&
ÞÞ
These are not the final page numbers!